Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Verge's AI-enabled CONVERGE platform identified and validated the targets, with 83% of prioritized targets validated in disease-relevant models.On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies' collaboration, which was initiated in July 2021.
在周三，Verge Genomics宣布，礼来（纽交所：LLY）选择继续开发针对运动神经元病（ALS）两个已验证药物靶点的治疗方法，这一合作始于2021年7月。
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a nervous system disease that affects the nerve cells in the brain and spinal cord.
运动神经元病（ALS），也称为卢·盖里希病，是一种影响大脑和脊髓神经细胞的神经系统疾病。
Also Read: Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
另请阅读：礼来的研究药物将粘性胆固醇水平降低了近86%。
Verge's AI-enabled CONVERGE platform identified and validated the targets, with 83% of prioritized targets validated in disease-relevant models.
Verge的人工智能驱动的CONVERGE平台识别并验证了这些靶点，83%的优先靶点在与疾病相关的模型中得到了验证。
Target selection triggered near-term milestone payments from Lilly to Verge. As the programs progress, Verge is eligible for additional downstream economics.
靶点选择触发了礼来对Verge的短期里程碑支付。随着项目的推进，Verge有资格获得额外的下游收益。
In 2021, Verge and Lilly entered a three-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development.
在2021年，Verge和礼来达成了为期三年的合作，以发现和验证用于ALS的新型治疗靶点，这将成为后续药物发现和开发的重点。
Verge received up to $25 million in upfront equity investment and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties.
Verge获得了最高达2500万美元的前期股权投资和潜在的短期里程碑，总交易价值为69400万美元，加上潜在的下游版税。
Verge also continues to advance VRG50635, its internal lead drug candidate for sporadic and familial ALS.
Verge还在推进其内部领先药物候选VRG50635，用于散发性和家族性ALS。
VRG50635 is currently being evaluated in a Phase 1B Proof-of-Concept (PoC) study in Canada and several European countries. Enrollment is complete and dose escalation, including to the highest dose level, is ongoing.
VRG50635目前正在加拿大和多个欧洲国家进行第10亿阶段的概念板块（PoC）研究。招募已完成，剂量递增，包括最高剂量的递增，仍在进行中。
Price Action: Eli Lilly stock is up 2.75% at about $749 at the last check Wednesday.
价格动态：礼来股票在周三最后一次检查时上涨2.75%，约为749美元。
- Global-E Soars: Q3 Sales Surge 32%, FY24 Outlook Raised Amid GMV Boom
- 全球货币-E飙升：第三季度销售激增32%，全年展望在GMV激增中上调
